|
Market Closed -
Other stock markets
|
After hours 02:11:46 pm | |||
| 28.74 EUR | +3.60% |
|
28.74 | 0.00% |
| Dec. 10 | Medincell Narrows Operating Loss in First Half | |
| Dec. 10 | MedinCell Says Partner Filed US FDA Application for Once-monthly Schizophrenia Treatment | MT |
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -21.13 | -32.5 | -40.78 | -39.49 | -10.56 | |||||
Return on Total Capital | -27.39 | -40.5 | -60.63 | -66.61 | -17.98 | |||||
Return On Equity % | 540.19 | 1.17K | 115.01 | 60.25 | 64.48 | |||||
Return on Common Equity | 540.19 | 1.17K | 115.01 | 60.25 | 64.48 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 100 | 100 | 100 | 100 | 100 | |||||
SG&A Margin | 64.33 | 207.43 | 71.15 | 98.72 | 51.13 | |||||
EBITDA Margin % | -123.69 | -664.78 | -168.81 | -167.82 | -36.32 | |||||
EBITA Margin % | -130.51 | -685.87 | -175.94 | -175.3 | -38.81 | |||||
EBIT Margin % | -130.51 | -685.87 | -175.94 | -175.3 | -38.81 | |||||
Income From Continuing Operations Margin % | -161.53 | -606.36 | -234.42 | -209.61 | -66.5 | |||||
Net Income Margin % | -161.53 | -606.36 | -234.42 | -209.61 | -66.5 | |||||
Net Avail. For Common Margin % | -161.53 | -606.36 | -234.42 | -209.61 | -66.5 | |||||
Normalized Net Income Margin | -99.69 | -443.82 | -146.25 | -130.35 | -41.02 | |||||
Levered Free Cash Flow Margin | -47.99 | -438.24 | -120.81 | -88.75 | 17.09 | |||||
Unlevered Free Cash Flow Margin | -28.98 | -410.07 | -102.82 | -64.59 | 28.56 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.26 | 0.08 | 0.37 | 0.36 | 0.44 | |||||
Fixed Assets Turnover | 2.98 | 0.75 | 2.04 | 2.02 | 5.18 | |||||
Receivables Turnover (Average Receivables) | 10.89 | 4.86 | 6.84 | 4.16 | 9.41 | |||||
Inventory Turnover (Average Inventory) | - | - | - | - | - | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 4.14 | 0.89 | 0.34 | 1.66 | 2.7 | |||||
Quick Ratio | 4.01 | 0.84 | 0.33 | 1.59 | 2.66 | |||||
Operating Cash Flow to Current Liabilities | -0.89 | -0.56 | -0.37 | -0.72 | 0.65 | |||||
Days Sales Outstanding (Average Receivables) | 33.51 | 75.05 | 53.37 | 88.08 | 38.78 | |||||
Days Outstanding Inventory (Average Inventory) | - | - | - | - | - | |||||
Average Days Payable Outstanding | - | - | - | - | - | |||||
Cash Conversion Cycle (Average Days) | - | - | - | - | - | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 486.15 | -355.18 | -136.44 | -158.5 | -411.33 | |||||
Total Debt / Total Capital | 82.94 | 139.19 | 374.4 | 270.94 | 132.12 | |||||
LT Debt/Equity | 446.12 | -143.19 | -33.7 | -143.41 | -366.76 | |||||
Long-Term Debt / Total Capital | 76.11 | 56.11 | 92.47 | 245.14 | 117.81 | |||||
Total Liabilities / Total Assets | 85.98 | 130.18 | 244.16 | 210.49 | 118.09 | |||||
EBIT / Interest Expense | -4.29 | -15.22 | -6.11 | -4.54 | -2.12 | |||||
EBITDA / Interest Expense | -3.97 | -14.48 | -5.73 | -4.21 | -1.84 | |||||
(EBITDA - Capex) / Interest Expense | -4.15 | -15.36 | -5.88 | -4.28 | -1.99 | |||||
Total Debt / EBITDA | -3.05 | -1.78 | -2.56 | -3.33 | -7.18 | |||||
Net Debt / EBITDA | 0.46 | -0.78 | -2.27 | -2.33 | 0.49 | |||||
Total Debt / (EBITDA - Capex) | -2.91 | -1.68 | -2.5 | -3.28 | -6.65 | |||||
Net Debt / (EBITDA - Capex) | 0.44 | -0.74 | -2.22 | -2.29 | 0.45 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 96.25 | -50.02 | 63.77 | -12.52 | 132.12 | |||||
Gross Profit, 1 Yr. Growth % | 96.25 | -50.02 | 63.77 | -12.52 | 132.12 | |||||
EBITDA, 1 Yr. Growth % | -20.69 | 50.06 | 0.44 | -13.04 | -49.76 | |||||
EBITA, 1 Yr. Growth % | -19.85 | 48.25 | 0.89 | -12.84 | -48.61 | |||||
EBIT, 1 Yr. Growth % | -19.85 | 48.25 | 0.89 | -12.84 | -48.61 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -20.47 | 30.65 | 29.04 | -21.78 | -26.36 | |||||
Net Income, 1 Yr. Growth % | -20.47 | 30.65 | 29.04 | -21.78 | -26.36 | |||||
Normalized Net Income, 1 Yr. Growth % | -11.79 | 30.06 | 28.82 | -22.03 | -26.95 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -27.5 | 16.01 | 27.27 | -30.67 | -29.38 | |||||
Accounts Receivable, 1 Yr. Growth % | 42.42 | -9.51 | 161.95 | 7.69 | 39.62 | |||||
Inventory, 1 Yr. Growth % | - | - | - | - | - | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -4.96 | 82.48 | -9.37 | -14.74 | -2.94 | |||||
Total Assets, 1 Yr. Growth % | 132.93 | -30.35 | -33.78 | 25.93 | 144.81 | |||||
Tangible Book Value, 1 Yr. Growth % | -142.54 | -296.79 | 194.07 | -2.14 | -56.06 | |||||
Common Equity, 1 Yr. Growth % | -155.87 | -246.5 | 216.31 | -3.48 | -59.91 | |||||
Cash From Operations, 1 Yr. Growth % | -3.21 | 76.05 | -1.67 | -43.24 | -263.27 | |||||
Capital Expenditures, 1 Yr. Growth % | 12.17 | 151.63 | -64.51 | -43.75 | 130.56 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -50.78 | 127.64 | 8.01 | -35.74 | -144.7 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -66.42 | 197.64 | -0.58 | -45.04 | -202.63 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 70.57 | -17.43 | 29.15 | 19.69 | 42.5 | |||||
Gross Profit, 2 Yr. CAGR % | 72.26 | -17.43 | 29.15 | 19.69 | 42.5 | |||||
EBITDA, 2 Yr. CAGR % | -1.17 | 21.69 | 12.78 | -6.54 | -33.9 | |||||
EBITA, 2 Yr. CAGR % | -0.45 | 20.97 | 12.67 | -6.22 | -33.07 | |||||
EBIT, 2 Yr. CAGR % | -0.45 | 20.97 | 12.67 | -6.22 | -33.07 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -1.7 | 1.85 | 29.85 | 0.47 | -24.1 | |||||
Net Income, 2 Yr. CAGR % | -1.71 | 1.85 | 29.85 | 0.47 | -24.1 | |||||
Normalized Net Income, 2 Yr. CAGR % | -0.96 | 16.81 | 19.6 | 0.22 | -24.53 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -13.03 | -8.33 | 21.51 | -6.14 | -30.03 | |||||
Accounts Receivable, 2 Yr. CAGR % | 51.84 | 13.52 | 53.96 | 67.96 | 22.62 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 7.76 | 31.69 | 28.6 | -12.1 | -9.03 | |||||
Total Assets, 2 Yr. CAGR % | 29.41 | 27.37 | -32.08 | -8.68 | 75.58 | |||||
Tangible Book Value, 2 Yr. CAGR % | 24.45 | -7.21 | 140.56 | 69.64 | -34.43 | |||||
Common Equity, 2 Yr. CAGR % | 19.51 | -8.46 | 115.27 | 74.73 | -37.79 | |||||
Cash From Operations, 2 Yr. CAGR % | -12.72 | 30.52 | 31.57 | -25.29 | -3.74 | |||||
Capital Expenditures, 2 Yr. CAGR % | 70.07 | 68.01 | -5.5 | -55.32 | 13.88 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -32.19 | 24.96 | 44.73 | -16.69 | -46.4 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -44.21 | 28.5 | 57.83 | -26.08 | -24.9 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 12.36 | 0.36 | 31.54 | 13.42 | 49.26 | |||||
Gross Profit, 3 Yr. CAGR % | 13.36 | 1.02 | 31.54 | 13.42 | 49.26 | |||||
EBITDA, 3 Yr. CAGR % | 31.03 | 22.17 | 7.87 | 3.42 | -24.01 | |||||
EBITA, 3 Yr. CAGR % | 30.17 | 21.86 | 7.81 | 3.43 | -23.26 | |||||
EBIT, 3 Yr. CAGR % | 30.17 | 21.86 | 7.81 | 3.43 | -23.26 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 25.71 | 8.02 | 10.21 | 9.66 | -9.42 | |||||
Net Income, 3 Yr. CAGR % | 25.72 | 8.01 | 10.21 | 9.66 | -9.42 | |||||
Normalized Net Income, 3 Yr. CAGR % | 28.83 | 14.91 | 14.49 | 3.71 | -9.8 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 9.17 | -4.3 | 2.27 | 0.73 | -14.63 | |||||
Accounts Receivable, 3 Yr. CAGR % | 106.01 | 27.78 | 50.01 | 36.67 | 57.92 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 12.24 | 28.44 | 16.27 | 12.14 | -9.15 | |||||
Total Assets, 3 Yr. CAGR % | 35.88 | 5.27 | 2.42 | -16.56 | 26.86 | |||||
Tangible Book Value, 3 Yr. CAGR % | -18.65 | 46.35 | 36.3 | 78.25 | 8.14 | |||||
Common Equity, 3 Yr. CAGR % | -8.87 | 28.9 | 38.39 | 64.76 | 6.97 | |||||
Cash From Operations, 3 Yr. CAGR % | 30.78 | 10.27 | 18.76 | -0.59 | -3.05 | |||||
Capital Expenditures, 3 Yr. CAGR % | 4.95 | 93.79 | 0.06 | -20.51 | -22.79 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 4.77 | 13.41 | 12.84 | 10.41 | -32.3 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -3.18 | 15.24 | 11.38 | 11.03 | -17.54 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 4.88 | -16.29 | 10.47 | 24.17 | 35.82 | |||||
Gross Profit, 5 Yr. CAGR % | 4.88 | -14.72 | 11.06 | 24.66 | 35.82 | |||||
EBITDA, 5 Yr. CAGR % | 89.89 | 55.03 | 28.92 | 6.09 | -11.32 | |||||
EBITA, 5 Yr. CAGR % | 105.34 | 52.54 | 28.09 | 6.19 | -10.91 | |||||
EBIT, 5 Yr. CAGR % | 105.34 | 50.88 | 28.09 | 6.19 | -10.91 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 100.64 | 47.63 | 27.3 | 4.93 | -5.07 | |||||
Net Income, 5 Yr. CAGR % | 98.19 | 47.43 | 27.31 | 4.93 | -5.07 | |||||
Normalized Net Income, 5 Yr. CAGR % | 117.12 | 42.61 | 29.47 | 5.41 | -3.09 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 84.83 | 31.95 | 13.93 | -5.04 | -12.16 | |||||
Accounts Receivable, 5 Yr. CAGR % | -16.35 | -3.05 | 83.35 | 42.54 | 38.39 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 20.8 | 23.13 | 18.52 | 10.37 | 5.4 | |||||
Total Assets, 5 Yr. CAGR % | 41.6 | 13.75 | 2.96 | -0.55 | 27.07 | |||||
Tangible Book Value, 5 Yr. CAGR % | 169.77 | 30.87 | 26.22 | 55.26 | 1.71 | |||||
Common Equity, 5 Yr. CAGR % | 48.37 | 41.8 | 29.12 | 45.58 | 0.51 | |||||
Cash From Operations, 5 Yr. CAGR % | 182.04 | 44.48 | 31.09 | -5.63 | 9.19 | |||||
Capital Expenditures, 5 Yr. CAGR % | -4.52 | 3.81 | 0.64 | 7.76 | 5.37 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | - | 28.48 | 27.41 | -2.92 | -16.22 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | 31.26 | 30.15 | -6.78 | -4.86 |
- Stock Market
- Equities
- MEDCL Stock
- Financials MedinCell S.A.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















